AU2013256757B2 - Process for purifying recombinant Plasmodium falciparum circumsporozoite protein - Google Patents

Process for purifying recombinant Plasmodium falciparum circumsporozoite protein Download PDF

Info

Publication number
AU2013256757B2
AU2013256757B2 AU2013256757A AU2013256757A AU2013256757B2 AU 2013256757 B2 AU2013256757 B2 AU 2013256757B2 AU 2013256757 A AU2013256757 A AU 2013256757A AU 2013256757 A AU2013256757 A AU 2013256757A AU 2013256757 B2 AU2013256757 B2 AU 2013256757B2
Authority
AU
Australia
Prior art keywords
days
rcsp
recombinant
falciparum circumsporozoite
circumsporozoite protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013256757A
Other languages
English (en)
Other versions
AU2013256757A1 (en
Inventor
Jeffrey Allen
Greg CANTIN
Ryan HAVERSTOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfenex Inc
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of AU2013256757A1 publication Critical patent/AU2013256757A1/en
Application granted granted Critical
Publication of AU2013256757B2 publication Critical patent/AU2013256757B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013256757A 2012-05-01 2013-04-22 Process for purifying recombinant Plasmodium falciparum circumsporozoite protein Ceased AU2013256757B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261641105P 2012-05-01 2012-05-01
US61/641,105 2012-05-01
US13/844,261 US9169304B2 (en) 2012-05-01 2013-03-15 Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US13/844,261 2013-03-15
PCT/US2013/037656 WO2013165732A1 (en) 2012-05-01 2013-04-22 Process for purifying recombinant plasmodium falciparum circumsporozoite protein

Publications (2)

Publication Number Publication Date
AU2013256757A1 AU2013256757A1 (en) 2014-10-30
AU2013256757B2 true AU2013256757B2 (en) 2017-02-16

Family

ID=49514758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013256757A Ceased AU2013256757B2 (en) 2012-05-01 2013-04-22 Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Country Status (16)

Country Link
US (2) US9169304B2 (enExample)
EP (1) EP2844666B1 (enExample)
JP (1) JP6238967B2 (enExample)
KR (1) KR102087461B1 (enExample)
CN (1) CN104379596B (enExample)
AR (1) AR090900A1 (enExample)
AU (1) AU2013256757B2 (enExample)
BR (1) BR112014027019B1 (enExample)
CA (1) CA2870198C (enExample)
MX (1) MX352093B (enExample)
MY (1) MY166380A (enExample)
NZ (1) NZ630121A (enExample)
SG (1) SG11201407108TA (enExample)
TW (1) TWI630213B (enExample)
WO (1) WO2013165732A1 (enExample)
ZA (1) ZA201407420B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
EP3092002B1 (en) * 2014-01-09 2019-09-25 Kentucky Bioprocessing, Inc. Method of purifying monoclonal antibodies
JP2017512477A (ja) * 2014-03-28 2017-05-25 コンジュゴン，インコーポレーテッド 治療細菌の小型コロニー変種の調製
WO2016089782A1 (en) 2014-12-01 2016-06-09 Pfenex Inc. Fusion partners for peptide production
CN109966319B (zh) * 2017-12-22 2022-11-22 四川好医生攀西药业有限责任公司 一种康复新液的原料及其制备方法和应用
CN108559721A (zh) * 2018-05-15 2018-09-21 北京师范大学 一种净化空气的复合微生物菌剂及其应用
CN116457012A (zh) * 2020-06-29 2023-07-18 帕斯公司 红细胞前期疟疾疫苗
CN114763542A (zh) * 2021-01-12 2022-07-19 正大天晴药业集团股份有限公司 利用酵母胞内表达制备黄曲霉尿酸氧化酶的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) * 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
ZA855232B (en) 1984-07-23 1986-02-26 Univ New York Protective peptide antigen corresponding to plasmodium falciparum circumsporozoite protein
US5178861A (en) 1984-09-12 1993-01-12 New York University Cross-reactive and protective epitopes of circumsporozoite proteins
ZA856655B (en) 1984-09-12 1986-04-30 Univ New York Cross-reactive and protective epitopes of circumsporozoite proteins
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
AU590599B2 (en) 1985-07-12 1989-11-09 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
CA1340373C (en) 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0252588A3 (en) 1986-05-12 1989-07-12 Smithkline Beecham Corporation Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
FI884485A7 (fi) 1987-01-30 1988-09-29 Smithkline Biologicals S A P. falciparumin sporotsoiitin pintaproteiinin muodostuminen hiivassa
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
AU625713B2 (en) 1988-02-19 1992-07-16 Microgenesys, Inc. Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5028425A (en) 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria
DE68927933T2 (de) * 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
JPH03504082A (ja) 1988-12-21 1991-09-12 スミスクライン・バイオロジカルズ 昆虫細胞によるプラスモディウム属サーカムスポロゾイト蛋白の発現
AU5027890A (en) 1989-02-10 1990-09-05 Genesit Oy A method for producing pertussis toxin subunits
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
NZ233255A (en) 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
DE69002817T2 (de) 1989-11-28 1993-12-09 Wellcome Found Vakzine.
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
AU1762092A (en) 1991-04-01 1992-11-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
DK0725653T3 (da) 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US20040214157A1 (en) 1994-06-29 2004-10-28 Simon C. Burton Chromatographic resins and methods for using same
US5652348A (en) 1994-09-23 1997-07-29 Massey University Chromatographic resins and methods for using same
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
US5932714A (en) 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
HUP0200302A2 (en) 1999-02-18 2002-05-29 Rmf Dictagene Sa Malaria vaccine
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7781186B2 (en) 2000-09-25 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Screening methods using normal human liver cell line
AU2001293074A1 (en) 2000-09-25 2002-04-08 Walter Reed Army Institute Of Research Human liver cell line
US7363166B2 (en) * 2001-03-30 2008-04-22 Council Of Scientific & Industrial Research Computational method for the identification of candidate proteins useful as anti-infectives
SE0104353D0 (sv) 2001-12-19 2001-12-19 Amersham Biosciences Ab Separation method
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
US20040067880A1 (en) 2002-10-04 2004-04-08 Kuo Macus Tien Prodrug therapy of liver diseases using receptor-mediated delivery of malarial circumsporozoite protein as a carrier
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8232255B2 (en) 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EP1573012B1 (en) 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
EP1692282B1 (en) 2003-11-19 2012-08-08 Pfenex, Inc. Improved protein expression systems in auxotrophic Pseudomonas fluorescens
BRPI0416807A (pt) 2003-11-21 2007-01-09 Dow Global Technologies Inc sistemas de expressão aperfeiçoados com secreção de sistema sec
WO2005063805A1 (en) 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
KR101183720B1 (ko) 2004-01-16 2012-09-17 다우 글로벌 테크놀로지스 엘엘씨 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
JP2008510465A (ja) 2004-08-20 2008-04-10 ケイエムティー ヒパテック インコーポレイテッド キメラヒト肝臓を有するマラリア動物モデル
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
US7790186B2 (en) 2005-01-18 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Plasmodium vivax hybrid circumsporozoite protein and vaccine
EP1754717A1 (en) 2005-08-19 2007-02-21 Université de Lausanne Antigenic peptides and their use
EP2264058A3 (en) 2005-09-30 2011-03-23 Seattle Biomedical Research Plasmodium liver stage antigens
US7749519B2 (en) 2005-12-09 2010-07-06 Kim Lee Sim Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
KR20090018799A (ko) 2006-05-30 2009-02-23 다우 글로벌 테크놀로지스 인크. 코돈 최적화 방법
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CL2008002361A1 (es) 2007-08-13 2009-08-07 Glaxosmithkline Biologicals Sa Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria.
WO2009114202A2 (en) 2008-03-14 2009-09-17 The United States Of America As Represented By The Secretary Of The Navy Vaccine and immunization method using plasmodium antigen 2
WO2010008764A1 (en) 2008-06-23 2010-01-21 Dow Global Technologies Inc. Pseudomonas fluorescens strains for production of extracellular recombinant protein
EP2350130B1 (en) 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
US8063193B2 (en) 2009-03-27 2011-11-22 Abbott Laboratories Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
MX2012010148A (es) 2010-03-04 2013-01-22 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
WO2011126811A2 (en) 2010-03-30 2011-10-13 Pfenex Inc. High level expression of recombinant toxin proteins
DK2385107T3 (en) * 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) * 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOLODNY N. et al., "Two-step chromatographic purification of recombinant Plasmodium falciparum circumsporozoite protein from Eschericihia coli", Journal of Chromatography B, 2001, Vol. 762, pages 77-86 *
PLASSMEYER M.L. et al., "Structure of the Plasmodium falciparum Circumsporozoite Protein, a Leading Malaria Vaccine Candidate", The Journal of Biological Chemistry, 2009, Vol. 284, No. 39, pages 26951-26963 *

Also Published As

Publication number Publication date
KR102087461B1 (ko) 2020-03-10
JP6238967B2 (ja) 2017-11-29
ZA201407420B (en) 2016-10-26
MX2014013124A (es) 2015-02-05
MX352093B (es) 2017-11-08
US20140051841A1 (en) 2014-02-20
MY166380A (en) 2018-06-25
CN104379596B (zh) 2018-05-29
AR090900A1 (es) 2014-12-17
NZ630121A (en) 2016-06-24
EP2844666A4 (en) 2015-11-04
US9169304B2 (en) 2015-10-27
US9849177B2 (en) 2017-12-26
EP2844666A1 (en) 2015-03-11
SG11201407108TA (en) 2014-11-27
CA2870198C (en) 2019-12-03
US20160051677A1 (en) 2016-02-25
KR20150027743A (ko) 2015-03-12
AU2013256757A1 (en) 2014-10-30
BR112014027019B1 (pt) 2022-09-06
CN104379596A (zh) 2015-02-25
CA2870198A1 (en) 2013-11-07
JP2015517464A (ja) 2015-06-22
TW201348250A (zh) 2013-12-01
TWI630213B (zh) 2018-07-21
WO2013165732A1 (en) 2013-11-07
EP2844666B1 (en) 2019-07-17
BR112014027019A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
US9849177B2 (en) Process for purifying recombinant plasmodium falciparum circumsporozoite protein
CA2656835C (en) Refolding of recombinant proteins
CA2220447C (en) Novel fusion protein recovery and purification methods
AU2016382134B2 (en) Peptide tag and tagged protein including same
CN111511756B (zh) 使用烷基糖苷类进行蛋白质纯化和病毒灭活
HU222666B1 (hu) Eljárás neuorotrofinok tisztítására
JP2010534690A (ja) 組み換え成長因子タンパク質の最適化した精製方法
US20190016754A1 (en) Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
TWI660042B (zh) 用以製備目標蛋白的表現構建體與方法
KR101527528B1 (ko) 가용성 재조합 단백질의 생산, 추출 및 정제 방법
JP2021511785A (ja) 組換えポリペプチド生産用ｎ末端融合パートナーおよびこれを用いた組換えポリペプチドの生産方法
CA2641372A1 (en) Affinity polypeptide for purification of recombinant proteins
US20220227805A1 (en) Methods of purifying charge-shielded fusion proteins
KR102011291B1 (ko) 신규한 융합 폴리펩타이드 및 이를 이용하여 인간 부갑상선 호르몬 1-34를 생산하는 방법
WO2022263559A1 (en) Production of cross-reactive material 197 fusion proteins
EP4630436A1 (en) Methods for expression of fusion-free bovine ultralong cdr3 scaffold

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired